151 related articles for article (PubMed ID: 17609682)
1. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
Fletcher CV; Brundage RC; Fenton T; Alvero CG; Powell C; Mofenson LM; Spector SA
Clin Pharmacol Ther; 2008 Feb; 83(2):300-6. PubMed ID: 17609682
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz liquid formulation in human immunodeficiency virus-infected children.
Starr SE; Fletcher CV; Spector SA; Brundage RC; Yong FH; Douglas SD; Flynn PM; Kline MW;
Pediatr Infect Dis J; 2002 Jul; 21(7):659-63. PubMed ID: 12237599
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Smith PF; Robbins GK; Shafer RW; Wu H; Yu S; Hirsch MS; Merigan TC; Park JG; Forrest A; Fischl MA; Morse GD;
Antimicrob Agents Chemother; 2005 Aug; 49(8):3558-61. PubMed ID: 16048984
[TBL] [Abstract][Full Text] [Related]
5. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Albrecht MA; Bosch RJ; Hammer SM; Liou SH; Kessler H; Para MF; Eron J; Valdez H; Dehlinger M; Katzenstein DA;
N Engl J Med; 2001 Aug; 345(6):398-407. PubMed ID: 11496850
[TBL] [Abstract][Full Text] [Related]
6. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
7. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.
Seminari E; Maggiolo F; Villani P; Suter F; Pan A; Regazzi MB; Paolucci S; Baldanti F; Tinelli C; Maserati R
J Acquir Immune Defic Syndr; 1999 Dec; 22(5):453-60. PubMed ID: 10961606
[TBL] [Abstract][Full Text] [Related]
8. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Cressey TR; Green H; Khoo S; Treluyer JM; Compagnucci A; Saidi Y; Lallemant M; Gibb DM; Burger DM;
Clin Infect Dis; 2008 May; 46(10):1601-8. PubMed ID: 18419497
[TBL] [Abstract][Full Text] [Related]
9. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Regazzi MB; Villani P; Maserati R; Seminari E; Pan A; LoCaputo F; Gambarana E; Fiocchi C
J Antimicrob Chemother; 2000 Mar; 45(3):343-7. PubMed ID: 10702554
[TBL] [Abstract][Full Text] [Related]
11. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Hsu A; Isaacson J; Brun S; Bernstein B; Lam W; Bertz R; Foit C; Rynkiewicz K; Richards B; King M; Rode R; Kempf DJ; Granneman GR; Sun E
Antimicrob Agents Chemother; 2003 Jan; 47(1):350-9. PubMed ID: 12499212
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
15. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086
[No Abstract] [Full Text] [Related]
16. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
Cohn SE; Park JG; Watts DH; Stek A; Hitti J; Clax PA; Yu S; Lertora JJ;
Clin Pharmacol Ther; 2007 Feb; 81(2):222-7. PubMed ID: 17192768
[TBL] [Abstract][Full Text] [Related]
17. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Litalien C; Faye A; Compagnucci A; Giaquinto C; Harper L; Gibb DM; Jacqz-Aigrain E;
Pediatr Infect Dis J; 2003 Jan; 22(1):48-55. PubMed ID: 12544409
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
[TBL] [Abstract][Full Text] [Related]
20. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
